Biblio Discovery — Demo Discovery Service

5 hasil untuk "Shuli Li"

Menampilkan 1–5 · 0,20 detik · RSS

  1. Artikel Jurnal Teks lengkap

    Mechanisms of melanocyte death in vitiligo

    Jianru Chen; Shuli Li; Chunying Li

    Medicinal Research Reviews · 2020 · Inggris · OpenAlex Scopus

    Abstract Vitiligo is an autoimmune depigment disease results from extensive melanocytes destruction. The destruction of melanocyte is thought to be of multifactorial causation. Genome‐wide associated studies have identified single‐nucleotide polymorphisms in a panel of susceptible loci as risk…

  2. Artikel Jurnal

    Phase II Randomized Trial of Transoral Surgery and Low-Dose Intensity Modulated Radiation Therapy in Resectable p16+ Locally Advanced Oropharynx Cancer: An ECOG-ACRIN Cancer Research Group Trial (E3311)

    Robert L. Ferris; Yael Flamand; Gregory S. Weinstein dkk.

    Journal of Clinical Oncology · 2021 · Inggris · OpenAlex Scopus

    PURPOSE: Definitive or postoperative chemoradiation (CRT) is curative for human papillomavirus-associated (HPV+) oropharynx cancer (OPC) but induces significant toxicity. As a deintensification strategy, we studied primary transoral surgery (TOS) and reduced postoperative radiation therapy (RT) in…

  3. Artikel Jurnal

    Dabrafenib and Trametinib in Patients With Tumors With BRAF V600E Mutations: Results of the NCI-MATCH Trial Subprotocol H

    April K.S. Salama; Shuli Li; Erin Renee Macrae dkk.

    Journal of Clinical Oncology · 2020 · Inggris · OpenAlex Scopus

    PURPOSE BRAF V600 mutations are commonly found in melanoma and thyroid cancers and to a lesser degree in other tumor types. Subprotocol H (EAY131-H) of the NCI-MATCH platform trial sought to investigate the selective BRAF inhibitor dabrafenib and the MEK1/2 inhibitor trametinib in patients with…

  4. Artikel Jurnal

    Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH)

    Keith T. Flaherty; Robert J. Gray; Alice P. Chen dkk.

    Journal of Clinical Oncology · 2020 · Inggris · OpenAlex Scopus

    PURPOSE: Therapeutically actionable molecular alterations are widely distributed across cancer types. The National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH) trial was designed to evaluate targeted therapy antitumor activity in underexplored cancer types. Tumor biopsy…

  5. Artikel Jurnal Teks lengkap

    The Molecular Analysis for Therapy Choice (NCI-MATCH) Trial: Lessons for Genomic Trial Design

    Keith T. Flaherty; Robert J. Gray; Alice P. Chen dkk.

    JNCI Journal of the National Cancer Institute · 2020 · Inggris · OpenAlex Scopus

    BACKGROUND: The proportion of tumors of various histologies that may respond to drugs targeted to molecular alterations is unknown. NCI-MATCH, a collaboration between ECOG-ACRIN Cancer Research Group and the National Cancer Institute, was initiated to find efficacy signals by matching patients with…